United states' food and drug administration, Federal agency

Curadev Pharma, a small molecule drug discovery and development company focused on the generation of novel therapeutics for the treatment of intractable diseases such as cancer has received a Study May Proceed letter from the United States Food and Drug Administration (FDA) to begin a Phase 1 study of its lead STING agonist CRD3874 in advanced/metastatic solid cancers. The study will be performed at a leading US cancer center.Successful clearance of tumors by the immune system requires the action of Type I IFNs. When activated in cells of the tumor microenvironment and lymph nodes, the immune adaptor protein STING coordinates proinflammatory immune responses by generating Type I IFNs and NF-kB activated cytokines. The human STING gene is polymorphic, with five major variants covering 98.8% of the population.CRD3874 is a potent allosteric activator of all major human STING variants covering 98.8% of the population and is differentiated from the CDN class of STING agonists. CRD3874 displays strong T cell dependent anti-tumor activity when dosed through either the IV or IT routes in a range of syngeneic tumor models as a single agent or in combination with checkpoint inhibitors. As would be anticipated for an immune-modulated mechanism of action, mice that experienced complete tumor regression on treatment were refractory to challenge from re-engrafted tumor cells."Immune evasion is an absolute requirement for the establishment of cancers. The systemic activation of STING by intravenous infusion of CRD3874-SI in patients with cancer is an attempt to re-activate dormant or disrupted immune mechanisms of tumor clearance," says Dr Arjun Surya, CEO & CSO of Curadev.Curadev is a small molecule drug discovery and development biotech with an exciting portfolio of research programs that have yielded patent protected drug candidates. Founded in 2010, Curadev has created a premier translational research organization known for prescient target selection and high quality, data-driven program execution. Programs at Curadev seek to ameliorate disease by translating cutting edge discoveries into new medicines. To know more about Curadev, visit our website .For enquiries:Manish Tandon,Co-Founder & CFOThis story is provided by PRNewswire.will not be responsible in any way for the content of this article. (ANI/PRNewswire)( With inputs from ANI )Disclaimer: This post has been auto-published from an agency feed without any modifications to the text and has not been reviewed by an editor

United States' Food And Drug AdministrationFOLLOW

United states' food and drug administration, Latest News

Mount Sinai researchers have made two important discoveries about the mechanism by which bladder cancer cells foil attacks from ... ...

Aurangabad Waluj police took action against two gutkha sellers and seized gutkha, banned in the state worth Rs 20,000 ... ...

Lokmat News Network Aurangabad Smoking and consuming tobacco in public places cost dearer to smokers and tobacco consumers. In ... ...

The domestic markets snapped their four-day losing run and ended with gains, picking up cues from the Monetary Policy ... ...

The domestic markets snapped their four-day losing run and ended with gains, picking up cues from the Monetary Policy ... ...

The United States Food and Drug Administration on Thursday listed the Halol facility in Gujarat of Sun Pharmaceuticals under ... ...

FDA issues notice on the backdrop of rising incidents of illegal sale of narcotic drugs Aurangabad: To curb the ... ...

Curadev Pharma, a small molecule drug discovery and development company focused on the generation of novel therapeutics for the treatment of intractable diseases such as cancer has received a Study May Proceed letter from the United States Food and D ...